Algernon Pharmaceuticals Inc AGNPF

Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > A Message To Board Director - Dr. Mark Williams, PhD, MBA

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Mar 29, 2023 2:40am

43 Views

Post# 35366248

RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA

Wrong as usual but don't let that stop you from trolling all over again. Also, who cares about arch? if anyone reads that board they'll see where your hype and river dances is complete nonsense. You act like your ridiculous posts are inside of an invisible thought bubble. LMAO. Go play elsewhere. Your shtick up your bum with me is long past needing removal.

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market